



NDA019414/S-022

**SUPPLEMENT APPROVAL**

Bracco Diagnostics, Inc.  
Attention: Melanie Benson, M.S., R.A.C.  
Director, US Regulatory Affairs  
259 Prospect Plains Road  
Monroe Township, NJ 08831

Dear Ms. Benson:

Please refer to your Supplemental New Drug Application (sNDA) dated March 29, 2019, received March 29, 2019, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for CardioGen®82 (Rubidium Rb 82 Generator).

We also refer to our letter dated March 15, 2019, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for CardioGen® 82 (Rubidium Rb 82 Generator) This information pertains to postmarketing adverse event reports of operator error related to the inappropriate use of calcium-containing solutions to elute the CardioGen generator. Use of calcium-containing eluents causes separation of strontium 82 and strontium 85 from the generator and exposes a patient to the serious risk of high levels of radioactivity.

This supplemental new drug application provides for revisions to the labeling for CardioGen-®82 (Rubidium Rb 82 Generator) and a saline tag for placement on the additive free 0.9% Sodium Chloride Injection USP container, consistent with our March 15, 2019 letter, and email dated March 26, 2019.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

## **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21CFR314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling text for the Prescribing Information, with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also, within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21CFR314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **SALINE TAG**

We acknowledge your March 29, 2019, submission containing the saline tag. Submit final printed Saline Tag identical to the enclosed Saline Tag, as soon as it is available, but no more than 30 days after they are printed.

## **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above, by fax to 301-847-8444, or electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft guidance for industry (available at: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf> ).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21CFR 314.80 and 314.81).

If you have any questions, call Rene' Tyson, Safety Regulatory Project Manager, at (301) 796-1476.

Sincerely,

*{See appended electronic signature page}*

Ira Krefting, M.D.  
Deputy Director for Safety  
Division of Medical Imaging Products  
Office of Drug Evaluation IV  
Center for Drug Evaluation and Research

### ENCLOSURE:

Content of Labeling  
Prescribing Information  
Saline Tag

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

IRA P KREFTING  
04/26/2019 03:27:22 PM